Daiichi Sankyo Company, Limited (TYO:4568)
2,884.50
+26.50 (0.93%)
Apr 7, 2026, 1:25 PM JST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 558.11B JPY in the quarter ending December 31, 2025, with 15.11% growth. This brings the company's revenue in the last twelve months to 2.05T, up 14.26% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
2.05T
Revenue Growth
+14.26%
P/S Ratio
2.55
Revenue / Employee
103.83M
Employees
19,765
Market Cap
5.24T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.89T | 284.57B | 17.77% |
| Mar 31, 2024 | 1.60T | 323.21B | 25.28% |
| Mar 31, 2023 | 1.28T | 233.59B | 22.36% |
| Mar 31, 2022 | 1.04T | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.47T |
| Astellas Pharma | 2.06T |
| Chugai Pharmaceutical | 1.26T |
| Ono Pharmaceutical | 509.35B |
| Kyowa Kirin | 496.83B |
| Santen Pharmaceutical | 287.99B |
| JCR Pharmaceuticals | 37.55B |
| Perseus Proteomics | 140.41M |
Daiichi Sankyo Company News
- 5 days ago - Nuvation Bio Acquires Japan Rights For Safusidenib; Now Owns Global Clinical Development Program - Nasdaq
- 12 days ago - Cathie Wood Chooses Medical AI Over Mark Zuckerberg: Ark Loads Up On TEM Stock, Dumps Meta Shares - Benzinga
- 12 days ago - Tempus AI (TEM) Partners with Daiichi Sankyo to Enhance Oncology Drug Development - GuruFocus
- 12 days ago - Tempus AI Enters Collaboration With Daiichi Sankyo - Nasdaq
- 20 days ago - Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs - Business Wire
- 21 days ago - Nikkei Rises 1.1%, Led by Shipping, Financial Stocks - WSJ
- 4 weeks ago - Daiichi Sankyo: FDA Grants Priority Review For ENHERTU - Nasdaq
- 4 weeks ago - GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. - Business Wire